{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:23Z","timestamp":1790688743604,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.metabol.2021.154867","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T23:42:58Z","timestamp":1629157378000},"page":"154867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Management of diabetic neuropathy"],"prefix":"10.1016","volume":"123","author":[{"given":"Simona","family":"Cernea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1210\/er.2018-00107","article-title":"Emerging biomarkers, tools, and treatments for diabetic polyneuropathy","volume":"40","author":"B\u00f6nhof","year":"2019","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","article-title":"Epidemiology of peripheral neuropathy and lower extremity disease in diabetes","volume":"19","author":"Hicks","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0030","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s001250050586","article-title":"Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study","volume":"39","author":"Tesfaye","year":"1996","journal-title":"Diabetologia."},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0035","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/dc13-1213","article-title":"Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for diabetes in youth follow-up cohort: a pilot study","volume":"36","author":"Jaiswal","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/oxfordjournals.aje.a115547","article-title":"Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley diabetes study","volume":"131","author":"Franklin","year":"1990","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2009.00200.x","article-title":"Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort","volume":"14","author":"Pop-Busui","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM199507133330203","article-title":"Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus","volume":"333","author":"Partanen","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.metabol.2021.154867_bb0060","doi-asserted-by":"crossref","first-page":"534372","DOI":"10.3389\/fpubh.2020.534372","article-title":"Prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the INTERPRET-DD study","volume":"8","author":"Lu","year":"2020","journal-title":"Front. Public Health"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc16-0081","article-title":"Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status","volume":"39","author":"Callaghan","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular risk factors and diabetic neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0080","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2337\/diab.38.11.1456","article-title":"Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study","volume":"38","author":"Maser","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154867_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-444-53480-4.00001-1","article-title":"Epidemiology of polyneuropathy in diabetes and prediabetes","volume":"126","author":"Ziegler","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0090","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jdi.12833","article-title":"Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications","volume":"9","author":"Kobayashi","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1073858408316175","article-title":"Neuronal targeting in diabetes mellitus: a story of sensory neurons and motor neurons","volume":"14","author":"Zochodne","year":"2008","journal-title":"Neuroscientist"},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.neuron.2017.02.005","article-title":"New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain","volume":"93","author":"Feldman","year":"2017","journal-title":"Neuron."},{"key":"10.1016\/j.metabol.2021.154867_bb0105","article-title":"Inflammatory markers associated with diabetes mellitus - old and new players","author":"Muzurovi\u0107","year":"2020","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40200-021-00734-1","article-title":"Inflammatory biomarkers as a part of diagnosis in diabetic peripheral neuropathy","volume":"20","author":"SL","year":"2021","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J Physiol Pharmacol"},{"issue":"7","key":"10.1016\/j.metabol.2021.154867_bb0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41574-021-00496-z","article-title":"Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy","volume":"17","author":"Sloan","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.metabol.2021.154867_bb0125","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1196\/annals.1338.067","article-title":"Role of advanced glycation end products and their receptors in development of diabetic neuropathy","volume":"1043","author":"Wada","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2011.137","article-title":"Diabetic neuropathy: cellular mechanisms as therapeutic targets","volume":"7","author":"Vincent","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"13\u201314","key":"10.1016\/j.metabol.2021.154867_bb0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.lfs.2011.02.003","article-title":"Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone","volume":"88","author":"Pratchayasakul","year":"2011","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0140","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.neuron.2013.01.012","article-title":"Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy","volume":"77","author":"Viader","year":"2013","journal-title":"Neuron."},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0145","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.2337\/db09-0047","article-title":"Dyslipidemia-induced neuropathy in mice: the role of oxLDL\/LOX-1","volume":"58","author":"Vincent","year":"2009","journal-title":"Diabetes."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuint.2010.10.012","article-title":"7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-\u03baB and Akt pathways","volume":"58","author":"Jang","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.metabol.2021.154867_bb0155","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3389\/fnins.2018.01038","article-title":"Functional and structural changes of the blood-nerve-barrier in diabetic neuropathy","volume":"12","author":"Richner","year":"2019","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0160","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jdi.12833","article-title":"Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications","volume":"9","author":"Kobayashi","year":"2018","journal-title":"J Diabetes Investig."},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0165","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2337\/diabetes.52.10.2615","article-title":"Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man","volume":"52","author":"Thrainsdottir","year":"2003","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154867_bb0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1744-8069-4-10","article-title":"Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies","volume":"4","author":"Jimenez-Andrade","year":"2008","journal-title":"Mol. Pain"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.mcna.2018.10.006","article-title":"Peripheral neuropathy","volume":"103","author":"Barrell","year":"2019","journal-title":"Med Clin North Am"},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0180","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/dom.12535","article-title":"Burning through the pain: treatments for diabetic neuropathy","volume":"17","author":"Javed","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0185","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdi.13401","article-title":"Current concepts in the management of diabetic polyneuropathy","volume":"12","author":"Ziegler","year":"2021","journal-title":"J Diabetes Investig."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/dme.14194","article-title":"Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late","volume":"37","author":"Javed","year":"2020","journal-title":"Diabet. Med."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0195","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.metabol.2013.11.019","article-title":"A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis","volume":"63","author":"Tsapas","year":"2014","journal-title":"Metabolism."},{"issue":"1\u20132","key":"10.1016\/j.metabol.2021.154867_bb0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1900\/RDS.2015.12.63","article-title":"Treating diabetic neuropathy: present strategies and emerging solutions","volume":"12","author":"Javed","year":"2015","journal-title":"Rev. Diabet. Stud."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0205","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy","volume":"6","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"14","key":"10.1016\/j.metabol.2021.154867_bb0210","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0220","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC","volume":"64","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2015","journal-title":"Diabetes."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006559","article-title":"Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes","volume":"5","author":"Ziegler","year":"2015","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ana.410420509","article-title":"Long-term effects of pancreatic transplantation on diabetic neuropathy","volume":"42","author":"Navarro","year":"1997","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.metabol.2021.154867_bb0235","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00125-019-4897-y","article-title":"Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation","volume":"62","author":"Azmi","year":"2019","journal-title":"Diabetologia."},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0240","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.2337\/dc07-0206","article-title":"Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis","volume":"30","author":"Del Carro","year":"2007","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2021.154867_bb0245","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/dc07-2409","article-title":"Epidermal innervation in type 1 diabetic patients: a 2.5-year prospective study after simultaneous pancreas\/kidney transplantation","volume":"31","author":"Boucek","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154867_bb0250","doi-asserted-by":"crossref","first-page":"457912","DOI":"10.1155\/2008\/457912","article-title":"Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes","volume":"2008","author":"Ekberg","year":"2008","journal-title":"Exp. Diabetes Res."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0255","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2337\/diabetes.52.2.536","article-title":"Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes","volume":"52","author":"Ekberg","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154867_bb0260","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0265","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0270","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0275","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2337\/dc18-1560","article-title":"Improvement in neuropathy outcomes with normalizing HbA1c in patients with type 2 diabetes","volume":"42","author":"Ishibashi","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154867_bb0280","article-title":"Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control","author":"Ponirakis","year":"2021","journal-title":"J Diabetes Investig."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0285","doi-asserted-by":"crossref","first-page":"419","DOI":"10.23736\/S0026-4806.17.05257-0","article-title":"Advances in the management of diabetic neuropathy","volume":"108","author":"V\u00e1rkonyi","year":"2017","journal-title":"Minerva Med."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/jns.12387","article-title":"Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy","volume":"25","author":"Stino","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0300","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the steno-2 randomised trial","volume":"59","author":"G\u00e6de","year":"2016","journal-title":"Diabetologia."},{"issue":"7","key":"10.1016\/j.metabol.2021.154867_bb0305","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc13-1544","article-title":"Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe study","volume":"37","author":"Sandb\u00e6k","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0310","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00125-007-0919-2","article-title":"Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle diabetes study","volume":"51","author":"Davis","year":"2008","journal-title":"Diabetologia."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0315","first-page":"195","article-title":"Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial","volume":"37","author":"Zangiabadi","year":"2012","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.metabol.2021.154867_bb0320","first-page":"401","article-title":"Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled phase IIa study","volume":"7","author":"Hern\u00e1ndez-Ojeda","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2021.154867_bb0325","first-page":"756294","article-title":"Effects of Ezetimibe\/Simvastatin and Rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind","volume":"2015","author":"Villegas-Rivera","year":"2015","journal-title":"Placebo-Controlled Clinical Trial Oxid Med Cell Longev"},{"issue":"9145","key":"10.1016\/j.metabol.2021.154867_bb0330","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","article-title":"Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial","volume":"352","author":"Malik","year":"1998","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0335","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","article-title":"Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial","volume":"58","author":"Ruggenenti","year":"2011","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0340","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1464-5491.1995.tb00482.x","article-title":"Is ACE inhibition with lisinopril helpful in diabetic neuropathy?","volume":"12","author":"Reja","year":"1995","journal-title":"Diabet. Med."},{"key":"10.1016\/j.metabol.2021.154867_bb0345","doi-asserted-by":"crossref","first-page":"6719239","DOI":"10.1155\/2017\/6719239","article-title":"Efficacy of administration of an angiotensin converting enzyme inhibitor for two years on autonomic and peripheral neuropathy in patients with diabetes mellitus","volume":"2017","author":"Didangelos","year":"2017","journal-title":"J. Diabetes Res."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14656566.2020.1812578","article-title":"State-of-the-art pharmacotherapy for diabetic neuropathy","volume":"22","author":"Azmi","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0355","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-017-4253-z","article-title":"Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study","volume":"60","author":"Look AHEAD Research Group","year":"2017","journal-title":"Diabetologia."},{"issue":"9","key":"10.1016\/j.metabol.2021.154867_bb0360","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1007\/s11695-019-04004-1","article-title":"The effect of bariatric surgery on peripheral polyneuropathy: a systematic review and meta-analysis","volume":"29","author":"Aghili","year":"2019","journal-title":"Obes. Surg."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0365","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jdiacomp.2012.05.007","article-title":"The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy","volume":"26","author":"Kluding","year":"2012","journal-title":"J. Diabetes Complicat."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0370","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ana.24310","article-title":"Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients","volume":"77","author":"Singleton","year":"2015","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0375","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc06-0224","article-title":"Lifestyle intervention for pre-diabetic neuropathy","volume":"29","author":"Smith","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0380","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdiacomp.2005.07.005","article-title":"Exercise training can modify the natural history of diabetic peripheral neuropathy","volume":"20","author":"Balducci","year":"2006","journal-title":"J. Diabetes Complicat."},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0385","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0390","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10715769900300721","article-title":"Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy","volume":"31","author":"Reljanovic","year":"1999","journal-title":"Free Radic. Res."},{"issue":"8","key":"10.1016\/j.metabol.2021.154867_bb0395","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2337\/diacare.22.8.1296","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). ALADIN III study group. Alpha-lipoic acid in diabetic neuropathy","volume":"22","author":"Ziegler","year":"1999","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0400","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2337\/diacare.26.3.770","article-title":"The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial","volume":"26","author":"Ametov","year":"2003","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0405","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0410","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1530\/EJE-12-0555","article-title":"A systematic review and meta-analysis of \u03b1-lipoic acid in the treatment of diabetic peripheral neuropathy","volume":"167","author":"Han","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.metabol.2021.154867_bb0415","doi-asserted-by":"crossref","first-page":"456279","DOI":"10.1155\/2012\/456279","article-title":"Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials","volume":"2012","author":"Mijnhout","year":"2012","journal-title":"Int. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0420","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/papr.12054","article-title":"Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy","volume":"14","author":"Snedecor","year":"2014","journal-title":"Pain Pract"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03007995.2018.1497958","article-title":"Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review","volume":"35","author":"Amato Nesbit","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0430","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1464-5491.2004.01109.x","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis","volume":"21","author":"Ziegler","year":"2004","journal-title":"Diabet. Med."},{"issue":"9","key":"10.1016\/j.metabol.2021.154867_bb0435","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with \u03b1-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0440","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211012213","article-title":"Effects of alpha-lipoic acid treatment on serum progranulin levels and inflammatory markers in diabetic neuropathy","volume":"49","author":"N\u00e1dr\u00f3","year":"2021","journal-title":"J Int Med Res"},{"issue":"14","key":"10.1016\/j.metabol.2021.154867_bb0445","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.1074\/jbc.M600418200","article-title":"Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose","volume":"281","author":"Berrone","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0450","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nm834","article-title":"Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy","volume":"9","author":"Hammes","year":"2003","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0455","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/dmrr.860","article-title":"Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro","volume":"24","author":"Schmid","year":"2008","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.metabol.2021.154867_bb0460","doi-asserted-by":"crossref","first-page":"107543","DOI":"10.1016\/j.neuropharm.2019.02.025","article-title":"Thiamine and benfotiamine counteract ultrasound-induced aggression, normalize AMPA receptor expression and plasticity markers, and reduce oxidative stress in mice","volume":"156","author":"Gorlova","year":"2019","journal-title":"Neuropharmacology."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0465","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5414\/CPP43071","article-title":"Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study)","volume":"43","author":"Haupt","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0470","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0029-1211460","article-title":"A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy","volume":"104","author":"Stracke","year":"1996","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0475","first-page":"220","article-title":"Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy","volume":"49","author":"Winkler","year":"1999","journal-title":"Arzneimittelforschung."},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0480","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/s-2008-1065351","article-title":"Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study","volume":"116","author":"Stracke","year":"2008","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"3\u20134","key":"10.1016\/j.metabol.2021.154867_bb0485","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10354-011-0865-y","article-title":"Actovegin\u00ae: a biological drug for more than 5 decades","volume":"161","author":"Buchmayer","year":"2011","journal-title":"Wien. Med. Wochenschr."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0490","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0031-1291248","article-title":"Treatment with Actovegin\u00ae improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation","volume":"120","author":"Dieckmann","year":"2012","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2021.154867_bb0495","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc09-0545","article-title":"Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients","volume":"32","author":"Ziegler","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2021.154867_bb0500","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jdiacomp.2017.03.012","article-title":"Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy","volume":"31","author":"Ziegler","year":"2017","journal-title":"J. Diabetes Complicat."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0505","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0510","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2337\/diab.33.5.470","article-title":"Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil","volume":"33","author":"Tomlinson","year":"1984","journal-title":"Diabetes."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0515","first-page":"580","article-title":"Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy","volume":"53","author":"Greene","year":"1999","journal-title":"Zenarestat Study Group Neurology"},{"issue":"7","key":"10.1016\/j.metabol.2021.154867_bb0520","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/dc05-2370","article-title":"Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial","volume":"29","author":"Hotta","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154867_bb0525","article-title":"Aldose reductase inhibitors for the treatment of diabetic polyneuropathy","volume":"4","author":"Chalk","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0530","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-020-01259-2","article-title":"Treating pain in diabetic neuropathy: current and developmental drugs","volume":"80","author":"Alam","year":"2020","journal-title":"Drugs."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0535","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4093\/dmj.2013.37.5.375","article-title":"Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials","volume":"37","author":"Bansal","year":"2013","journal-title":"Diabetes Metab. J."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0540","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40520-017-0770-3","article-title":"Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders","volume":"30","author":"Sergi","year":"2018","journal-title":"Aging Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0545","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.28.1.89","article-title":"Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials","volume":"28","author":"Sima","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0550","first-page":"395","article-title":"Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind","volume":"13","author":"Didangelos","year":"2021","journal-title":"Placebo-Controlled Trial Nutrients"},{"issue":"24","key":"10.1016\/j.metabol.2021.154867_bb0555","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1212\/WNL.0000000000004033","article-title":"Effect of omega-3 supplementation on neuropathy in type 1 diabetes: a 12-month pilot trial","volume":"88","author":"Lewis","year":"2017","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0560","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.3390\/nu12113254","article-title":"Efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, and carnitine for 12 months in patients with diabetic neuropathy","volume":"12","author":"Didangelos","year":"2020","journal-title":"Nutrients."},{"key":"10.1016\/j.metabol.2021.154867_bb0565","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2015.03.037","article-title":"Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: a meta-analysis","volume":"594","author":"Jiang","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"27","key":"10.1016\/j.metabol.2021.154867_bb0570","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011390","article-title":"Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy: a meta-analysis","volume":"97","author":"Jiang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12918-018-0674-7","article-title":"Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone","volume":"13","author":"de Anda-J\u00e1uregui","year":"2019","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.metabol.2021.154867_bb0580","series-title":"Neuropathic pain in adults: pharmacological management in non-specialist settings. No. 173, London: National Institute for Health and Care Excellence (UK)","author":"NICE Clinical Guidelines","year":"2020"},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0585","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.pain.2013.06.004","article-title":"Interventional management of neuropathic pain: NeuPSIG recommendations","volume":"154","author":"Dworkin","year":"2013","journal-title":"Pain."},{"issue":"20","key":"10.1016\/j.metabol.2021.154867_bb0590","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0595","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","article-title":"Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex","volume":"42","author":"Fink","year":"2002","journal-title":"Neuropharmacology."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0600","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1570159X1201140117162802","article-title":"Pregabalin in neuropathic pain: evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0605","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00002508-200112000-00002","article-title":"Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature","volume":"17","author":"Mellegers","year":"2001","journal-title":"Clin. J. Pain"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0610","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0149-2918(03)90011-7","article-title":"Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials","volume":"25","author":"Backonja","year":"2003","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0615","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0620","first-page":"E705","article-title":"Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis","volume":"16","author":"Rudroju","year":"2013","journal-title":"Pain Physician"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0625","article-title":"Pregabalin for neuropathic pain in adults","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0630","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/jdi.13013","article-title":"Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients","volume":"10","author":"Baba","year":"2019","journal-title":"J Diabetes Investig."},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0635","article-title":"Oxcarbazepine for neuropathic pain","volume":"12","author":"Zhou","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0640","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/157015909790031201","article-title":"Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise","volume":"7","author":"Marks","year":"2009","journal-title":"Curr. Neuropharmacol."},{"issue":"9","key":"10.1016\/j.metabol.2021.154867_bb0645","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/M14-0511","article-title":"Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis","volume":"161","author":"Griebeler","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.metabol.2021.154867_bb0650","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"1","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.metabol.2021.154867_bb0655","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"Quilici","year":"2009","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0660","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2337\/dc06-2009","article-title":"Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain","volume":"30","author":"Ziegler","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0665","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/157488609787354404","article-title":"Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients","volume":"4","author":"Wasan","year":"2009","journal-title":"Curr. Drug Saf."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0670","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-7843.2005.pto_96696601.x","article-title":"Antidepressants in the treatment of neuropathic pain","volume":"96","author":"Sindrup","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.metabol.2021.154867_bb0675","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011003","article-title":"Desipramine for neuropathic pain in adults","volume":"2014","author":"Hearn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0680","first-page":"E1","article-title":"Relative efficacy and safety of pharmacotherapeutic interventions for diabetic peripheral neuropathy: a systematic review and Bayesian network meta-analysis","volume":"24","author":"Asrar","year":"2021","journal-title":"Pain Physician"},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0685","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011003","article-title":"Imipramine for neuropathic pain in adults","volume":"2014","author":"Hearn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2021.154867_bb0690","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40122-017-0091-4","article-title":"Pharmacotherapy for neuropathic pain: a review","volume":"6","author":"Fornasari","year":"2017","journal-title":"Pain Ther"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0695","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00702-020-02145-7","article-title":"Challenges of neuropathic pain: focus on diabetic neuropathy","volume":"127","author":"Rosenberger","year":"2020","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0700","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1185\/030079906X162674","article-title":"Randomized study of tramadol\/acetaminophen versus placebo in painful diabetic peripheral neuropathy","volume":"23","author":"Freeman","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0705","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1056-8727(00)00060-X","article-title":"Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy","volume":"14","author":"Harati","year":"2000","journal-title":"J. Diabetes Complicat."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0710","article-title":"Tramadol for neuropathic pain in adults","volume":"6","author":"Duehmke","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0715","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.metabol.2021.154867_bb0720","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.2337\/dc13-2291","article-title":"A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2021.154867_bb0725","article-title":"Opioids for neuropathic pain","volume":"2013","author":"McNicol","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.metabol.2021.154867_bb0730","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1432-1033.2004.04082.x","article-title":"Biochemical pharmacology of the vanilloid receptor TRPV1","volume":"271","author":"Cortright","year":"2004","journal-title":"An update Eur J Biochem"},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0735","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1001\/archinte.1991.00400110079017","article-title":"Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study","volume":"151","author":"The Capsaicin Study Group","year":"1991","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0740","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/papr.12013","article-title":"0.025% capsaicin gel for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial","volume":"13","author":"Kulkantrakorn","year":"2013","journal-title":"Pain Pract"},{"issue":"Pt 7","key":"10.1016\/j.metabol.2021.154867_bb0745","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/brain\/awh175","article-title":"The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy","volume":"127","author":"Polydefkis","year":"2004","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0750","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14737175.2021.1874920","article-title":"A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults","volume":"21","author":"Abrams","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"21\u221222","key":"10.1016\/j.metabol.2021.154867_bb0755","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4414\/smw.2010.12995","article-title":"5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review","volume":"140","author":"Wolff","year":"2010","journal-title":"Swiss Med. Wkly."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0760","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cts.12977","article-title":"Shin N; VM202 study group. Gene therapy for diabetic peripheral neuropathy: a randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor","volume":"14","author":"Kessler","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0765","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0770","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s13063-018-2959-y","article-title":"Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial","volume":"19","author":"Selvarajah","year":"2018","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0775","first-page":"151","article-title":"Treating diabetic peripheral neuropathic pain","volume":"82","author":"Lindsay","year":"2010","journal-title":"Am. Fam. Physician"},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0780","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/dme.13083","article-title":"Systematic review of treatments for diabetic peripheral neuropathy","volume":"33","author":"\u00c7akici","year":"2016","journal-title":"Diabet. Med."},{"issue":"20","key":"10.1016\/j.metabol.2021.154867_bb0785","first-page":"30210","article-title":"The effects of psychological interventions on diabetic peripheral neuropathy: a systematic review and meta-analysis","volume":"S1524-9042","author":"Racaru","year":"2020","journal-title":"Pain Manag Nurs"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0790","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1590\/S1413-35552012005000083","article-title":"Electrical stimulation and electromagnetic field use in patients with diabetic neuropathy: systematic review and meta-analysis","volume":"17","author":"Stein","year":"2013","journal-title":"Braz J Phys Ther"},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0795","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/193229681300700510","article-title":"Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy","volume":"7","author":"Thakral","year":"2013","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.metabol.2021.154867_bb0800","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000002262","article-title":"Spinal cord stimulation for the management of painful diabetic neuropathy: a systematic review and meta-analysis of individual patient and aggregate data","author":"Duarte","year":"2021","journal-title":"Pain."},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0805","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2337\/diacare.26.5.1553","article-title":"Diabetic autonomic neuropathy","volume":"26","author":"Vinik","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0810","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/diacare.7.5.447","article-title":"Autonomic neural dysfunction in recently diagnosed diabetic subjects","volume":"7","author":"Pfeifer","year":"1984","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0815","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4997\/jrcpe.2020.310","article-title":"Diabetic autonomic neuropathy: a clinical update","volume":"50","author":"Sharma","year":"2020","journal-title":"J R Coll Physicians Edinb"},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0820","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1570161116666180829120101","article-title":"Cardiovascular autonomic neuropathy and distal symmetric sensorimotor polyneuropathy: these two diabetic microvascular complications do not invariably co-exist","volume":"18","author":"Pafili","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0825","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14797\/mdcj-14-4-251","article-title":"Cardiac autonomic neuropathy in diabetes mellitus","volume":"14","author":"Agashe","year":"2018","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0830","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc09-1294","article-title":"Cardiac autonomic neuropathy in diabetes: a clinical perspective","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.metabol.2021.154867_bb0835","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/dmrr.1239","article-title":"Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management","volume":"27","author":"Spallone","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0840","doi-asserted-by":"crossref","DOI":"10.3949\/ccjm.68.11.928","article-title":"Recognizing and treating diabetic autonomic neuropathy","volume":"68","author":"Vinik","year":"2001","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.metabol.2021.154867_bb0845","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fnins.2018.00591","article-title":"Cardiac autonomic neuropathy in diabetes: a predictor of cardiometabolic events","volume":"12","author":"Vinik","year":"2018","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0850","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4093\/dmj.2018.0259","article-title":"Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet","volume":"43","author":"Spallone","year":"2019","journal-title":"Diabetes Metab. J."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0855","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s001250050924","article-title":"The effect of intensive diabetes therapy on measures of autonomic nervous system function in the diabetes control and complications trial (DCCT)","volume":"41","author":"The Diabetes Control and Complications Trial Research Group","year":"1998","journal-title":"Diabetologia."},{"issue":"22","key":"10.1016\/j.metabol.2021.154867_bb0860","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","article-title":"Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the diabetes Control and complications trial\/epidemiology of diabetes interventions and complications study (DCCT\/EDIC)","volume":"119","author":"Pop-Busui","year":"2009","journal-title":"Circulation."},{"issue":"6","key":"10.1016\/j.metabol.2021.154867_bb0865","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/00007890-199403270-00008","article-title":"Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life","volume":"57","author":"Hathaway","year":"1994","journal-title":"Transplantation."},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0870","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/00007890-199912270-00005","article-title":"Changes in patterns of 24-hr heart rate variability after kidney and kidney-pancreas transplant","volume":"68","author":"Cashion","year":"1999","journal-title":"Transplantation."},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2021.154867_bb0875","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1007\/BF00587636","article-title":"Diabetic autonomic neuropathy after pancreas and kidney transplantation","volume":"34","author":"Boucek","year":"1991","journal-title":"Diabetologia."},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0880","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0041-1345(03)00447-0","article-title":"Spectral analysis of heart rate variation following simultaneous pancreas and kidney transplantation","volume":"35","author":"Boucek","year":"2003","journal-title":"Transplant. Proc."},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2021.154867_bb0885","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1007\/BF00587635","article-title":"Effect of pancreatic and\/or renal transplantation on diabetic autonomic neuropathy","volume":"34","author":"Nusser","year":"1991","journal-title":"Diabetologia."},{"key":"10.1016\/j.metabol.2021.154867_bb0890","article-title":"Cardiac autonomic neuropathy is not reversed by euglycemia following islet transplantation","author":"Deshmukh","year":"2020","journal-title":"Transplantation."},{"issue":"5\u20136","key":"10.1016\/j.metabol.2021.154867_bb0895","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1056-8727(99)00062-8","article-title":"The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM)","volume":"13","author":"Azad","year":"1999","journal-title":"J. Diabetes Complicat."},{"issue":"12","key":"10.1016\/j.metabol.2021.154867_bb0900","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11892-017-0959-z","article-title":"Cardiorespiratory fitness and cardiac autonomic function in diabetes","volume":"17","author":"R\u00f6hling","year":"2017","journal-title":"Curr Diab Rep"},{"issue":"5","key":"10.1016\/j.metabol.2021.154867_bb0905","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154211","article-title":"Bariatric surgery restores cardiac and Sudomotor autonomic C-fiber dysfunction towards normal in obese subjects with type 2 diabetes","volume":"11","author":"Casellini","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0910","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/diacare.20.3.355","article-title":"Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy","volume":"20","author":"Kontopoulos","year":"1997","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0915","first-page":"201","article-title":"Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy","volume":"53","author":"Athyros","year":"1998","journal-title":"Acta Cardiol."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0920","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/1570161117666190521101342","article-title":"Treatment of diabetic cardiovascular autonomic, peripheral and painful neuropathy. Focus on the treatment of cardiovascular autonomic neuropathy with ACE inhibitors","volume":"18","author":"Didangelos","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.metabol.2021.154867_bb0925","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.605681","article-title":"Improvement in cardiovascular autonomic neuropathy after high-dose vitamin D supplementation in patients with type 1 diabetes","volume":"11","author":"Silva","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0930","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087096","article-title":"Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.metabol.2021.154867_bb0935","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4093\/dmj.2017.41.4.275","article-title":"Effects of high-dose \u03b1-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea","volume":"41","author":"Lee","year":"2017","journal-title":"Diabetes Metab. J."},{"issue":"3","key":"10.1016\/j.metabol.2021.154867_bb0940","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/diacare.20.3.369","article-title":"Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN study). Deutsche Kardiale Autonome Neuropathie","volume":"20","author":"Ziegler","year":"1997","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.metabol.2021.154867_bb0945","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehy037","article-title":"2018 ESC guidelines for the diagnosis and management of syncope","volume":"39","author":"Brignole","year":"2018","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.metabol.2021.154867_bb0950","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1007\/s00125-011-2282-6","article-title":"The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis","volume":"54","author":"Sharma","year":"2011","journal-title":"Diabetologia."},{"issue":"1","key":"10.1016\/j.metabol.2021.154867_bb0955","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdiacomp.2012.08.001","article-title":"Prevalence of abnormal gastric emptying in asymptomatic women with newly detected diabetes and its reversibility after glycemic control-a prospective case control study","volume":"27","author":"Laway","year":"2013","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.metabol.2021.154867_bb0960","doi-asserted-by":"crossref","first-page":"102718","DOI":"10.1016\/j.autneu.2020.102718","article-title":"Gastrointestinal autonomic neuropathy in diabetes","volume":"229","author":"Marathe","year":"2020","journal-title":"Auton. Neurosci."},{"issue":"2","key":"10.1016\/j.metabol.2021.154867_bb0965","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrendo.2014.202","article-title":"Gastric emptying and glycaemia in health and diabetes mellitus","volume":"11","author":"Phillips","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.metabol.2021.154867_bb0970","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fphar.2010.00136","article-title":"Bladder dysfunction in diabetes mellitus","volume":"1","author":"Golbidi","year":"2010","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.metabol.2021.154867_bb0975","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3760\/cma.j.issn.0366-6999.20132407","article-title":"Diabetic bladder dysfunction","volume":"127","author":"Liu","year":"2014","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.metabol.2021.154867_bb0980","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03176472?recrs=ab&type=Intr&cond=Diabetic+Neuropathies&draw=4&rank=53; accessed on 05.08.2021."},{"key":"10.1016\/j.metabol.2021.154867_bb0985","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04688671; accessed on 05.08.2021."},{"key":"10.1016\/j.metabol.2021.154867_bb0990","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04707157?recrs=ab&type=Intr&cond=Diabetic+Neuropathies&draw=3&rank=57; accessed on 05.08.2021."},{"key":"10.1016\/j.metabol.2021.154867_bb0995","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04146896?recrs=ab&type=Intr&cond=Diabetic+Neuropathies&draw=5; accessed on 05.08.2021."},{"key":"10.1016\/j.metabol.2021.154867_bb1000","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002066-14\/DE; accessed on 05.08.2021."},{"key":"10.1016\/j.metabol.2021.154867_bb1005","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04469270?recrs=ab&type=Intr&cond=Diabetic+Neuropathies&draw=3; accessed on 05.08.2021."},{"issue":"929","key":"10.1016\/j.metabol.2021.154867_bb1010","article-title":"New perspective in diabetic neuropathy: from the periphery to the brain, a call for early detection, and precision medicine","volume":"10","author":"Yang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:29:48Z","timestamp":1758428988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":202,"alternative-id":["S0026049521001670"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154867","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of diabetic neuropathy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154867"}}